Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Single-Arm Clinical Study of Anti-thymocyte Globulin-based Conditioning Regimen Combined With Post-Transplantation Cyclophosphamide for GVHD Prevention in Allogeneic HSCT After PD-1 Blockade

NCT06238245 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT06238245
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06238245 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Single-Arm Clinical Study of Anti-thymocyte Globulin-based Conditioning Regimen Combined With Post-Transplantation Cyclophosphamide for GVHD Prevention in Allogeneic HSCT After PD-1 Blockade
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
February 28, 2024
Completion date
June 30, 2026
Enrollment
22 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

graft-versus-host disease, hematological malignancies